INTELLECTUAL PROPERTY
A globally covered patent estate
Four patent families map to the platform's scientific functions, with a foundation priority from November 2012 that predates known third-party work in deaminase-based cancer diagnostics.
45
Active patent assets
36
Granted or validated
11 + EP
National jurisdictions plus European Patent coverage
2012
Earliest priority date
FAMILY 1
Somatic mutagenesis cause
Foundational Targeted Somatic Mutation methods for identifying the deaminase sources of mutation.
Priority Nov 2012
19 assets
FAMILY 2
Cancer recurrence detection
Recurrence monitoring via deaminase signatures.
Priority Aug 2015
11 assets
FAMILY 3
Predicting therapy efficacy
Cancer-Progression Associated Signatures (C-PAS) for response prediction.
Priority Nov 2017
9 assets
FAMILY 4
Cancer progression prediction
Progression prediction and prognostic risk stratification at diagnosis.
Priority Jun 2020
6 assets
Owned in full by GMDx Co Pty Ltd. No university obligations and no litigation history.
COMPLEMENTARY BY DESIGN
A foundational layer the rest of the field can build on
Codon-context causality is additive to the technologies leading precision oncology today. It supplies the mechanistic ground truth that each of these layers is otherwise missing.
AI GENOMICS INFRASTRUCTURE
Ground-truth causality for foundation models
AI-native genomic models learn from patterns; they lack biological causality. GMDx's Targeted Somatic Mutation methods and 20,000+ patient reference database supply causal labels and training signal.
PRECISION DIAGNOSTICS
A validated differentiator above TMB
Diagnostics competing to outperform TMB and PD-L1 for immunotherapy response gain a validated AUC 0.86 method and a mechanistic interpretation layer.
SEQUENCING & PIPELINES
Clinical value in hard settings
ML-driven somatic variant callers gain clinical meaning when paired with deaminase-signature attribution, particularly in low tumour-purity and immunotherapy indications.
PHARMA & DRUG DEVELOPMENT
The companion-diagnostic measurement layer
Checkpoint-inhibitor franchises depend on identifying responders, and every deaminase-modulator programme needs to stratify patients by signature. GMDx provides that layer.